Literature DB >> 8500229

Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood.

S Urien1, F Brée, F Breillout, G Bastian, A Krikorian, J P Tillement.   

Abstract

Using [3H]-vinorelbine, we demonstrated the presence of saturable and time-dependent high-affinity binding sites on human platelets and lymphocytes. The dissociation constant and binding-site values observed were 200 +/- 38 nM, 20.0 +/- 2.2 amol/platelet, and 155 +/- 20 amol/lymphocyte, respectively. Among other blood components, saturable low-affinity binding of vinorelbine to alpha 1-acid glycoprotein, serum albumin, and lipoproteins was observed. The binding to erythocytes was nonsaturable. Given the relative concentrations of these carriers, vinorelbine mainly distributes in the platelet compartment in blood (> 70%), and the amount of free vinorelbine in plasma relative to the total amount in blood is < 2%. It is suggested that because of the preferential retention of vinorelbine by platelets, variations in the platelet count are very likely to produce changes in the free blood fraction of vinorelbine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500229     DOI: 10.1007/BF00685841

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Pharmacokinetics and metabolism of Navelbine.

Authors:  A Krikorian; R Rahmani; M Bromet; P Bore; J P Cano
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

2.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.

Authors:  M Masquelier; S Vitols; C Peterson
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

4.  Interaction of vinblastine, vincristine and colchicine with serum proteins.

Authors:  D W Donigian; R J Owellen
Journal:  Biochem Pharmacol       Date:  1973-09-01       Impact factor: 5.858

5.  Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells.

Authors:  P W Gout; L L Wijcik; C T Beer
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

7.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts.

Authors:  S G Vitols; M Masquelier; C O Peterson
Journal:  J Med Chem       Date:  1985-04       Impact factor: 7.446

9.  Binding of indapamide to serum proteins and erythrocytes.

Authors:  S Urien; P Riant; A Renouard; B Coulomb; I Rocher; J P Tillement
Journal:  Biochem Pharmacol       Date:  1988-08-01       Impact factor: 5.858

10.  Binding of vinca alkaloid analogues to human serum albumin and to alpha 1-acid glycoprotein.

Authors:  I Fitos; J Visy; M Simonyi
Journal:  Biochem Pharmacol       Date:  1991-02-01       Impact factor: 5.858

  10 in total
  10 in total

1.  In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors:  O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

4.  Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

Authors:  W Linkesch; M Weger; I Eder; H W Auner; C Pernegg; C Kraule; M J Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

Review 5.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Authors:  Laurent Nguyen; Brigitte Tranchand; Christian Puozzo; Philippe Variol
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

7.  Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Authors:  T Schilling; H H Fiebig; S Kerpel-Fronius; B Winterhalter; P Variol; P Tresca; B Heinrich; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.

Authors:  Mourad Hamimed; Pierre Leblond; Aurélie Dumont; Florence Gattacceca; Emmanuelle Tresch-Bruneel; Alicia Probst; Pascal Chastagner; Anne Pagnier; Emilie De Carli; Natacha Entz-Werlé; Jacques Grill; Isabelle Aerts; Didier Frappaz; Anne-Isabelle Bertozzi-Salamon; Caroline Solas; Nicolas André; Joseph Ciccolini
Journal:  Cancer Chemother Pharmacol       Date:  2022-06-25       Impact factor: 3.288

Review 9.  Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.

Authors:  S O'Reilly; M J Kennedy; E K Rowinsky; R C Donehower
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis.

Authors:  Aurélie Pétain; Dafang Zhong; Xiaoyan Chen; Zhang Li; Shao Zhimin; Jiang Zefei; Grégoire Zorza; Pierre Ferré
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-27       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.